Accolade Inc
NASDAQ:ACCD
Accolade Inc
Cost of Revenue
Accolade Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Accolade Inc
NASDAQ:ACCD
|
Cost of Revenue
-$198.9m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
DaVita Inc
NYSE:DVA
|
Cost of Revenue
-$8.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cost of Revenue
-$6.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
|
CVS Health Corp
NYSE:CVS
|
Cost of Revenue
-$307.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-11%
|
|
Cigna Corp
NYSE:CI
|
Cost of Revenue
-$170.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cost of Revenue
-$8.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-9%
|
See Also
What is Accolade Inc's Cost of Revenue?
Cost of Revenue
-198.9m
USD
Based on the financial report for Feb 28, 2023, Accolade Inc's Cost of Revenue amounts to -198.9m USD.
What is Accolade Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-30%
Over the last year, the Cost of Revenue growth was -18%. The average annual Cost of Revenue growth rates for Accolade Inc have been -39% over the past three years , -30% over the past five years .